Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Treatments: Alendronate; Calcium; Calcium Carbonate; Calcium, Dietary; Diphosphonates; Ergocalciferols; Pancrelipase; Vitamin D; Vitamins; Zoledronic Acid

Criteria

Inclusion Criteria:

• Transplant patients who have had a kidney or kidney/pancreas transplant in the last 150 days with adequate kidney function as defined by a calculated creatine clearance of 35ml/min or more and serum creatinine less than 3.0

Exclusion Criteria:

• Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower

• History of more than one vertebral or non-vertebral fracture in the past two years

• Abnormalities of the esophagus which delay esophageal emptying

• Inability to stay upright for 30 minutes

• Pregnant, nursing women or women not using an effective form of birth control

• Hypocalcemia

• Hypercalcemia

• Calculated creatinine clearance of <35 ml/min or serum creatinine > 3.0

• Patients already treated with bisphosphonates within the past one year

• Patients unable to undergo DXA

• Patients with cancer